HUP0003405A2 - Szabályozott hatóanyag-leadású, szublingvális vagy bukkális adagolású gyógyszerkészítmények - Google Patents

Szabályozott hatóanyag-leadású, szublingvális vagy bukkális adagolású gyógyszerkészítmények

Info

Publication number
HUP0003405A2
HUP0003405A2 HU0003405A HUP0003405A HUP0003405A2 HU P0003405 A2 HUP0003405 A2 HU P0003405A2 HU 0003405 A HU0003405 A HU 0003405A HU P0003405 A HUP0003405 A HU P0003405A HU P0003405 A2 HUP0003405 A2 HU P0003405A2
Authority
HU
Hungary
Prior art keywords
sublingual
water
buccal
adminisration
hydrochloride
Prior art date
Application number
HU0003405A
Other languages
English (en)
Inventor
Ragab El-Rashidy
Emad Eldin Hassan
Bruce Ronsen
Original Assignee
Pentech Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pentech Pharmaceuticals, Inc. filed Critical Pentech Pharmaceuticals, Inc.
Publication of HUP0003405A2 publication Critical patent/HUP0003405A2/hu
Publication of HUP0003405A3 publication Critical patent/HUP0003405A3/hu
Publication of HU225108B1 publication Critical patent/HU225108B1/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Abstract

A találmány vízben oldódó hatóanyagok szabályozott leadására képes,szublingvális vagy bukkális adagolású gyógyszerkészítményekrevonatkozik. A találmány szerinti gyógyszerkészítmények lényegében azalábbi összetevőkből állnak: egy vízben oldódó hatóanyagból, amelyapomorfin-hidroklorid, albuterol-szulfát, timolol-maleát, verapamil-hidroklorid vagy naloxon-hidroklorid; egy ozmotikus szerből; egyduzzadásra képes hidrofil hordozóanyagból; és egy vízbendiszpergálható polimerből; a készítmények T90-értéke a körülbelül 25és körülbelül 300 közötti tartományba esik; és a készítményekben azozmotikus szer tömege a duzzadásra képes hidrofil hordozóanyagtömegének körülbelül 0,3-körülbelül 4-szerese. A találmány szerinti készítmények pszichés eredetű impotencia ésParkinson-kór hatékony kezelésére alkalmazhatók. Ó
HU0003405A 1997-04-29 1998-04-29 Controlled release of drugs delivered by sublingual or buccal adminisration HU225108B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/841,250 US5888534A (en) 1995-06-13 1997-04-29 Controlled release of drugs delivered by sublingual or buccal administration
PCT/US1998/008630 WO1998048781A1 (en) 1997-04-29 1998-04-29 Controlled release of drugs delivered by sublingual or buccal administration

Publications (3)

Publication Number Publication Date
HUP0003405A2 true HUP0003405A2 (hu) 2001-02-28
HUP0003405A3 HUP0003405A3 (en) 2001-04-28
HU225108B1 HU225108B1 (en) 2006-06-28

Family

ID=25284405

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0003405A HU225108B1 (en) 1997-04-29 1998-04-29 Controlled release of drugs delivered by sublingual or buccal adminisration

Country Status (23)

Country Link
US (1) US5888534A (hu)
EP (1) EP1017371B1 (hu)
JP (1) JP4948691B2 (hu)
CN (1) CN1135103C (hu)
AR (1) AR012615A1 (hu)
AT (1) ATE244000T1 (hu)
BR (1) BR9808703A (hu)
CA (1) CA2289260C (hu)
CO (1) CO4940397A1 (hu)
CZ (1) CZ292513B6 (hu)
DE (1) DE69816103T2 (hu)
DK (1) DK1017371T3 (hu)
ES (1) ES2201487T3 (hu)
HK (1) HK1031334A1 (hu)
HU (1) HU225108B1 (hu)
IL (1) IL132646A0 (hu)
NO (1) NO995302L (hu)
NZ (1) NZ501114A (hu)
PL (1) PL336759A1 (hu)
PT (1) PT1017371E (hu)
TW (1) TW430562B (hu)
WO (1) WO1998048781A1 (hu)
ZA (1) ZA983548B (hu)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6436950B1 (en) * 1998-08-14 2002-08-20 Nastech Pharmaceutical Company, Inc. Nasal delivery of apomorphine
UA67802C2 (uk) 1998-10-23 2004-07-15 Пфайзер Рісьоч Енд Дівелепмент Компані, Н.В./С.А. Фармацевтична композиція з контрольованим вивільненням інгібітора цгмф фде-5 (варіанти), спосіб її одержання та спосіб лікування еректильної дисфункції
US20030083231A1 (en) * 1998-11-24 2003-05-01 Ahlem Clarence N. Blood cell deficiency treatment method
US6291471B1 (en) 1998-12-17 2001-09-18 Abb Holdings, Inc. Use of apomorphine for the treatment of organic erectile dysfunction in males
FI109453B (fi) 1999-06-30 2002-08-15 Orion Yhtymae Oyj Farmaseuttinen koostumus
BR0109515A (pt) 2000-04-07 2004-08-10 Tap Pharmaceutical Prod Inc Derivados da apomorfina e métodos para seu uso
CA2429047A1 (en) * 2000-11-15 2002-05-23 Tap Pharmaceutical Products, Inc. Treatment of anti-depression drug-induced sexual dysfunction with apomorphine
US20030022912A1 (en) * 2001-02-08 2003-01-30 Martino Alice C. Rapid-onset medicament for treatment of sexual dysfunction
US20060073174A1 (en) * 2001-08-16 2006-04-06 Access Pharmaceuticals, Inc. Adherent and erodible film to treat a moist surface of a body tissue
US6585997B2 (en) 2001-08-16 2003-07-01 Access Pharmaceuticals, Inc. Mucoadhesive erodible drug delivery device for controlled administration of pharmaceuticals and other active compounds
ES2426723T3 (es) * 2001-10-17 2013-10-24 Takeda Pharmaceutical Company Limited Gránulos que contienen gran cantidad de compuesto químico inestable en medio ácido
DE60308647T2 (de) * 2002-02-07 2007-08-09 Pharmacia Corp. Pharmazeutische darreichungsform zur mukosalen verabreichung
BR0308567A (pt) * 2002-03-19 2007-01-09 Michael Holick derivados de glicosìdeo e glicosìdeo de ortoéster de apomorfina, análogos, e seus usos
US20040109889A1 (en) * 2002-12-04 2004-06-10 Bunick Frank J. Surface treatment composition for soft substrates
US7306812B2 (en) 2003-05-09 2007-12-11 Cephalon, Inc. Dissolvable backing layer for use with a transmucosal delivery device
US7276246B2 (en) * 2003-05-09 2007-10-02 Cephalon, Inc. Dissolvable backing layer for use with a transmucosal delivery device
CA2491665A1 (fr) * 2004-12-24 2006-06-24 Louis Cartilier Formulation de comprime pour liberation soutenue de principe actif
EP1917000A2 (en) * 2005-07-07 2008-05-07 Farnam Companies, Inc. Sustained release pharmaceutical compositions for highly water soluble drugs
US20070020186A1 (en) * 2005-07-22 2007-01-25 Alpex Pharma S.A. Solid dosage formulations of narcotic drugs having improved buccal adsorption
JP2009149524A (ja) * 2006-03-16 2009-07-09 Kyushu Univ アルツハイマー病の予防・治療剤
GB2437488A (en) * 2006-04-25 2007-10-31 Optinose As Pharmaceutical oily formulation for nasal or buccal administration
WO2009148442A1 (en) 2008-06-04 2009-12-10 Colgate-Palmolive Company Oral care implement with cavitation system
US20130213393A1 (en) 2009-12-22 2013-08-22 Evoke Pharma, Inc. Nasal formulations of metoclopramide
CN101475145B (zh) * 2009-01-20 2014-10-22 同济大学 一种具有磁热和靶向药物缓释特性的水滑石及其制备方法
KR20120042836A (ko) * 2009-06-12 2012-05-03 아다지오 파마슈티컬즈 엘티디 설하 아포모르핀
SG10201405392RA (en) * 2009-09-04 2014-10-30 Munisekhar Medasani Method of treatment of neurodegenerative or neuro-muscular degenerative diseases andtherapeutic agent to treat the same
JP5892940B2 (ja) 2009-11-25 2016-03-23 アリスジェン ソシエテ アノニム クラウン化合物及び／又は対イオンと複合体化されたペプチドを含む粘膜送達組成物
KR101890317B1 (ko) 2010-12-16 2018-08-22 선오비온 파마슈티컬스 인코포레이티드 설하 필름
US20130071477A1 (en) 2011-09-19 2013-03-21 Orexo Ab New abuse-resistant pharmaceutical composition for the treatment of opioid dependence
US20140256822A1 (en) * 2013-03-11 2014-09-11 Pharmaceutical Productions Inc. Transmucosal drug delivery system
CA3019769C (en) 2015-04-21 2021-10-12 Sunovion Pharmaceuticals Inc. Methods of treating parkinson's disease by administration of apomorphine to an oral mucosa
CA3047088A1 (en) 2016-12-15 2018-06-21 Evoke Pharma, Inc. Treatment of moderate and severe gastroparesis
US20220249465A1 (en) * 2019-05-31 2022-08-11 Primo Pharmatech Llc Unit dosage form for transmucosal drug delivery of an active pharmaceutical ingredient

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2818855A (en) * 1954-02-11 1958-01-07 Anthony P Miller Surgical device
US3428728A (en) * 1965-10-21 1969-02-18 Hans Lowey Timed release sublingual medications
US4127118B1 (en) * 1977-03-16 1995-12-19 Alvaro Latorre Method of effecting and enhancing an erection
US4801587A (en) * 1987-03-02 1989-01-31 Gene Voss Impotence ointment
US5256652A (en) * 1987-11-12 1993-10-26 Pharmedic Co. Topical compositions and methods for treatment of male impotence
US5419917A (en) * 1994-02-14 1995-05-30 Andrx Pharmaceuticals, Inc. Controlled release hydrogel formulation
DE10199068I2 (de) * 1994-04-22 2004-05-06 Pentech Pharmaceuticals Inc Sublinguale Dosierungsformen enthaltend apomorphinzur Verwendung bei der Behandlung von erektiler D ysfunktion.
US5624677A (en) * 1995-06-13 1997-04-29 Pentech Pharmaceuticals, Inc. Controlled release of drugs delivered by sublingual or buccal administration
GB9517062D0 (en) * 1995-08-18 1995-10-25 Scherer Ltd R P Pharmaceutical compositions

Also Published As

Publication number Publication date
CA2289260A1 (en) 1998-11-05
NO995302L (no) 1999-12-27
PL336759A1 (en) 2000-07-17
CZ292513B6 (cs) 2003-10-15
US5888534A (en) 1999-03-30
PT1017371E (pt) 2003-10-31
TW430562B (en) 2001-04-21
EP1017371A4 (en) 2000-07-12
EP1017371B1 (en) 2003-07-02
WO1998048781A1 (en) 1998-11-05
IL132646A0 (en) 2001-03-19
NZ501114A (en) 2001-09-28
HU225108B1 (en) 2006-06-28
NO995302D0 (no) 1999-10-29
JP2001527546A (ja) 2001-12-25
CN1271276A (zh) 2000-10-25
HUP0003405A3 (en) 2001-04-28
DK1017371T3 (da) 2003-09-29
HK1031334A1 (en) 2001-06-15
ES2201487T3 (es) 2004-03-16
ATE244000T1 (de) 2003-07-15
ZA983548B (en) 1999-01-28
AR012615A1 (es) 2000-11-08
DE69816103T2 (de) 2004-04-15
CA2289260C (en) 2008-02-12
CZ386099A3 (cs) 2000-04-12
CO4940397A1 (es) 2000-07-24
EP1017371A1 (en) 2000-07-12
CN1135103C (zh) 2004-01-21
JP4948691B2 (ja) 2012-06-06
DE69816103D1 (de) 2003-08-07
BR9808703A (pt) 2001-11-20

Similar Documents

Publication Publication Date Title
HUP0003405A2 (hu) Szabályozott hatóanyag-leadású, szublingvális vagy bukkális adagolású gyógyszerkészítmények
ATE211385T1 (de) Anwendungsformen zur behandlung der männlichen erektilen dysfunktion
CA2345064A1 (en) Fentanyl composition for the treatment of acute pain
EP1649851A3 (en) Pregelatinized starch in a controlled release formulation
RU99117926A (ru) Лекарственные формы и способ лечения расстройства мужской эректильной функции
MX9801305A (es) Composicion de disolucion rapida oral para agonistas de dopamina.
HUP0203451A2 (hu) Új, tuberkolózis elleni gyógyszerkészítmények és eljárás előállításukra
HUP0203870A2 (hu) Adenozinreceptor agonistát vagy antagonistát tartalmazó gyógyászati készítmény
BR0308137A (pt) Formulações de droga de liberação constante contendo um peptìdeo veìculo
NO306894B1 (no) Anvendelse av galanthamin for fremstilling av en farmasöytisk formulering for behandling av nikotinavhengighet
TW228474B (hu)
WO2002034267A8 (de) Kombination eines transdermalen therapeutischen systems und einer oralen und/oder parenteralen zubereitung enthaltend dopaminagonisten zur behandlung dopaminerger erkrankungen
CA2383212A1 (en) Controlled release oral dosage suitable for oral administration
GB2328872B (en) Method for preparing pharmaceutical formulations
GEP20043377B (en) Pharmaceutical Complex

Legal Events

Date Code Title Description
MM4A Lapse of definitive patent protection due to non-payment of fees